(Q43666906)

25 November 2017

High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia (English)

1 reference

25 November 2017

1 reference

1 reference

1 reference

0 references

Cortes J

1

1 reference

25 November 2017

Estey E

2

1 reference

25 November 2017

O'Brien S

3

1 reference

25 November 2017

Giles F

4

1 reference

25 November 2017

Shen Y

5

1 reference

25 November 2017

Koller C

6

1 reference

25 November 2017

Beran M

7

1 reference

25 November 2017

Thomas D

8

1 reference

25 November 2017

Keating M

9

1 reference

25 November 2017

Kantarjian H

10

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 July 2001

1 reference

25 November 2017

1 reference

25 November 2017

92

1 reference

25 November 2017

1

1 reference

25 November 2017

7-14

1 reference

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

25 November 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Liposomes as carriers of cancer chemotherapy. Current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Anthracycline Efficacy in vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Phase I study of liposomal daunorubicin in patients with acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Estimated 6-year event-free survival of 55% in 60 consecutive adult acute lymphoblastic leukemia patients treated with an intensive phase II protocol based on high induction dose of daunorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Role of daunorubicin in the induction therapy for adult acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010701%2992%3A1%3C7%3A%3AAID-CNCR1285%3E3.0.CO%3B2-D

10.1002/1097-0142(20010701)92:1<7::AID-CNCR1285>3.0.CO;2-D

21 January 2018

Identifiers

DOI

1 reference

25 November 2017

1 reference